Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 15 February 2012
The Office of the Inspector General (OIG) of the US Department of Health and Human Services (DHHS) announced on 14 February that they have recovered over $4.1 billion from individuals and companies "who attempted to defraud seniors and taxpayers or who sought payments to which they were not entitled," including $1.3 billion from pharmaceutical and medical device manufacturers.
The amount marks the largest total amount recovered by OIG, which has heightened its enforcement activities in recent years thanks to a 2009 program known as the Health Care Fraud Prevention and Enforcement Action Team (HEAT) that provided them additional funding.
OIG noted that it obtained 21 criminal convictions involving pharmaceutical and medical device manufacturers and "$1.3 billion in criminal fines, forfeitures, restitution and disgorgement under the Food, Drug and Cosmetic Act (FD&C Act)." These actions were taken because of-among other reasons-illegal marketing and quality issues related to a product's strength, purity or quality.